Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase:ENEST1st sub-analysis

Autor: Maria Liz Paciello Coronel, Beatrice Vincenzi, Ljubomir Petrov, Fausto Castagnetti, Delphine Rea, Andrzej Hellmann, Francis J. Giles, Andreas Hochhaus, Valentin Garcia-Gutierrez, Maria Asuncion Echeveste Gutierrez, Franҫois-Xavier Mahon, Luca Dezzani, Philipp le Coutre, Gianantonio Rosti, Norbert Gattermann, Nicholas C.P. Cross, Jeroen Janssen

Publikováno v: Hochhaus, A, Mahon, F-X, le Coutre, P, Petrov, L, Janssen, J J W M, Cross, N C P, Rea, D, Castagnetti, F, Hellmann, A, Rosti, G, Gattermann, N, Coronel, M L P, Gutierrez, M A E, Garcia-Gutierrez, V, Vincenzi, B, Dezzani, L & Giles, F J 2017, ' Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase : ENEST1st sub-analysis ', Journal of Cancer Research and Clinical Oncology, vol. 143, no. 7, pp. 1225-1233 . https://doi.org/10.1007/s00432-017-2359-9
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Clinical Oncology, 143(7), 1225-1233. Springer Verlag
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid

PURPOSE: The ENEST1st sub-analysis presents data based on Philadelphia chromosome (Ph) status, i.e., Ph+ and Ph-/BCR-ABL1 + chronic myeloid leukemia.METHODS: Patients received nilotinib 300 mg twice daily, up to 24 months.RESULTS: At screening, 983 p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b32a0b316372c1eb5fd4577816af80c2
https://research.vumc.nl/en/publications/0d7cc258-28f1-462e-bdd2-52e52f3fc3b9